Human CPD/GP180 ORF/cDNA clone-Mammalian (Non-Viral Vector) plasmid (NM_001304.5)

Cat. No.: pGMPC001594
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human CPD/GP180 Non-Viral expression plasmid (overexpression vector) for mouse CPD overexpression in unique cell transient transfection and stable cell line development.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to CPD/GP180 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMPC001594
Gene Name CPD
Accession Number NM_001304.5
Gene ID 1362
Species Human
Product Type Mammalian (Non-Viral Vector) plasmid (overexpression)
Insert Length 4143 bp
Gene Alias GP180
Fluorescent Reporter EGFP
Mammalian Cell Selection Null
Fusion Tag 3xflag (C-Terminal)
Promoter EF1
Resistance Amplicin
ORF Nucleotide Sequence ATGGCGAGCGGCCGGGACGAGCGGCCGCCTTGGCGGCTAGGGCGGCTCCTGTTGCTCATGTGCCTGCTGCTGCTGGGGAGCTCGGCCCGGGCGGCTCACATCAAGAAGGCGGAGGCGACTACCACAACTACGAGCGCGGGCGCCGAGGCGGCCGAGGGCCAGTTCGACCGCTACTACCACGAAGAGGAGTTGGAGTCGGCGCTGAGGGAGGCGGCGGCCGCGGGCCTCCCCGGCCTGGCCCGCCTCTTTAGCATCGGCCGCTCGGTGGAAGGCCGGCCGCTGTGGGTGCTTCGCCTCACCGCCGGCCTGGGGTCGCTAATCCCTGAGGGCGACGCGGGGCCTGACGCTGCCGGGCCCGACGCTGCGGGGCCGCTGCTGCCCGGCCGGCCCCAGGTGAAGCTGGTGGGCAACATGCATGGCGACGAGACCGTGTCGCGCCAGGTGTTGATCTACTTGGCCCGCGAGCTGGCGGCCGGCTACCGCCGCGGGGACCCGCGCCTGGTCCGCCTGCTCAACACCACCGACGTGTACCTGCTGCCCAGCCTCAACCCCGATGGCTTCGAGCGTGCCCGCGAGGGCGACTGTGGCTTCGGCGACGGCGGCCCGTCCGGGGCCAGCGGCCGCGACAATAGTCGCGGCCGCGACCTCAACCGAAGCTTTCCCGACCAGTTTAGCACCGGCGAACCCCCCGCCCTGGACGAGGTGCCCGAGGTGCGCGCCCTCATCGAGTGGATCCGCAGGAACAAGTTTGTGCTTTCTGGAAATCTGCATGGTGGCTCAGTGGTAGCAAGCTATCCTTTTGATGATTCTCCAGAACATAAGGCCACTGGAATCTATAGCAAAACCTCAGATGATGAAGTATTTAAATACTTGGCAAAAGCTTATGCTTCAAACCACCCCATAATGAAAACTGGTGAGCCTCATTGTCCAGGAGATGAAGACGAGACTTTCAAAGATGGAATCACAAACGGCGCACATTGGTATGATGTGGAAGGTGGTATGCAAGATTACAATTATGTGTGGGCCAACTGTTTTGAGATCACATTAGAACTGTCTTGTTGCAAGTACCCACCTGCTTCACAGCTTCGACAGGAATGGGAGAACAATCGTGAGTCTTTGATCACATTGATTGAAAAGGTTCACATTGGAGTGAAAGGATTTGTTAAAGATTCCATAACAGGATCTGGGTTAGAGAATGCAACCATCTCAGTGGCTGGTATTAATCATAATATCACAACAGGCAGATTTGGTGATTTCTACCGATTACTTGTTCCTGGAACTTACAACCTTACAGTAGTTTTAACTGGGTATATGCCATTGACTGTTACTAATGTAGTGGTGAAAGAAGGACCAGCCACAGAGGTGGATTTTTCTCTTAGGCCAACTGTAACTTCAGTAATCCCTGACACGACAGAGGCTGTATCAACTGCTAGCACAGTTGCTATACCTAATATTCTTTCTGGAACATCATCCTCCTACCAGCCAATTCAGCCAAAGGACTTTCACCACCACCATTTCCCTGATATGGAAATCTTCTTGAGAAGGTTTGCCAATGAATATCCTAACATTACCCGGCTTTATTCCTTGGGAAAATCAGTAGAGTCAAGAGAACTTTATGTGATGGAGATATCTGATAATCCGGGTGTCCATGAACCAGGTGAACCAGAATTTAAGTACATTGGAAATATGCATGGAAATGAAGTGGTTGGAAGAGAACTGCTGTTGAACCTCATAGAATACCTTTGTAAGAACTTTGGAACAGACCCTGAAGTCACAGATTTGGTTCATAACACTAGAATTCACCTTATGCCATCCATGAATCCTGATGGGTATGAAAAGTCCCAGGAAGGAGATTCAATAAGTGTAATTGGCAGAAACAACAGCAACAACTTTGACCTGAACCGAAATTTCCCAGACCAGTTTGTTCAGATCACAGATCCTACGCAACCAGAAACTATTGCTGTAATGAGCTGGATGAAGTCCTATCCATTTGTACTTTCAGCAAACCTGCATGGAGGTTCTTTGGTGGTTAACTACCCTTTTGATGATGATGAACAAGGACTTGCCACATATAGTAAATCACCAGATGATGCTGTGTTCCAACAAATAGCACTTTCTTATTCCAAGGAAAATTCCCAGATGTTTCAAGGTAGACCTTGCAAGAATATGTATCCTAATGAATATTTTCCTCATGGAATAACAAATGGAGCTAGTTGGTATAATGTGCCAGGAGGAATGCAGGACTGGAACTATTTACAAACAAATTGCTTTGAAGTGACTATTGAACTAGGTTGTGTGAAATATCCACTTGAGAAAGAGCTGCCAAACTTTTGGGAACAGAATCGAAGATCACTAATCCAGTTTATGAAACAGGTTCATCAGGGCGTCAGAGGATTTGTTCTAGATGCCACAGATGGCAGGGGTATATTAAATGCCACCATTAGTGTTGCTGAGATTAATCACCCAGTGACTACTTACAAAACTGGAGATTACTGGCGTCTCTTGGTTCCAGGAACTTATAAAATCACAGCATCTGCTCGAGGGTATAATCCAGTTACCAAGAATGTGACTGTCAAGAGTGAAGGCGCTATTCAGGTCAACTTCACACTTGTTCGATCCTCAACAGATTCAAACAATGAATCAAAGAAAGGAAAAGGGGCTAGCAGCAGCACCAATGATGCCAGTGATCCAACTACTAAAGAGTTTGAAACTTTAATTAAAGACCTTTCAGCGGAGAATGGTTTGGAAAGCCTCATGTTACGCTCCTCCTCAAATCTGGCTCTGGCTCTTTATCGATACCATTCCTACAAAGACTTATCAGAGTTTCTGAGAGGACTTGTAATGAACTATCCACATATTACAAATCTTACCAATTTGGGACAGAGCACTGAATATCGTCACATTTGGTCCCTTGAAATCTCCAATAAGCCCAATGTATCTGAGCCTGAAGAACCAAAGATTCGTTTTGTTGCTGGTATCCATGGAAATGCGCCAGTTGGAACTGAACTGCTTTTGGCTCTGGCAGAATTTCTCTGCCTGAACTACAAAAAGAACCCAGCTGTTACCCAATTGGTTGACAGGACTAGGATTGTGATTGTCCCTTCTCTAAATCCAGATGGGCGAGAGAGAGCTCAAGAGAAAGACTGTACTTCAAAAATAGGACAAACAAATGCTCGTGGCAAAGATTTGGATACAGACTTCACAAATAATGCCTCCCAACCTGAGACCAAAGCCATCATTGAAAATTTGATTCAAAAACAGGACTTTAGTCTTTCTGTTGCCTTAGATGGTGGTTCCATGCTGGTCACATATCCTTATGACAAGCCAGTACAGACAGTGGAAAATAAAGAGACTCTGAAGCATTTGGCATCTCTTTATGCAAATAATCATCCATCCATGCACATGGGTCAGCCCAGTTGCCCAAATAAATCAGATGAGAATATTCCAGGAGGAGTAATGCGTGGAGCAGAATGGCATAGTCACCTGGGCAGCATGAAGGATTATAGTGTCACCTATGGCCATTGTCCGGAAATCACAGTATACACAAGCTGCTGTTACTTTCCTAGTGCTGCACGACTCCCTTCCTTGTGGGCAGACAATAAGAGATCTCTTCTTAGTATGTTAGTGGAGGTTCACAAGGGAGTTCATGGATTTGTTAAAGATAAGACTGGAAAGCCAATCTCTAAAGCAGTCATTGTACTTAATGAAGGAATAAAGGTACAAACAAAAGAGGGAGGTTATTTCCATGTACTCTTAGCGCCAGGTGTCCATAACATTATTGCCATCGCTGATGGGTACCAGCAACAACATTCACAGGTCTTTGTGCATCATGATGCAGCTAGTTCTGTGGTGATAGTCTTTGACACAGATAACCGGATATTTGGTTTGCCAAGGGAGCTTGTGGTAACTGTATCAGGTGCTACTATGTCGGCATTGATCCTAACAGCTTGCATTATTTGGTGCATCTGCTCAATCAAGTCTAATAGACACAAGGATGGCTTTCATCGGCTCAGGCAGCATCATGATGAGTATGAAGATGAAATTCGCATGATGTCTACCGGCTCCAAGAAGTCCCTCCTAAGCCATGAGTTCCAGGATGAAACAGACACTGAAGAGGAAACATTATATTCTAGCAAACATTGA
ORF Protein Sequence MASGRDERPPWRLGRLLLLMCLLLLGSSARAAHIKKAEATTTTTSAGAEAAEGQFDRYYHEEELESALREAAAAGLPGLARLFSIGRSVEGRPLWVLRLTAGLGSLIPEGDAGPDAAGPDAAGPLLPGRPQVKLVGNMHGDETVSRQVLIYLARELAAGYRRGDPRLVRLLNTTDVYLLPSLNPDGFERAREGDCGFGDGGPSGASGRDNSRGRDLNRSFPDQFSTGEPPALDEVPEVRALIEWIRRNKFVLSGNLHGGSVVASYPFDDSPEHKATGIYSKTSDDEVFKYLAKAYASNHPIMKTGEPHCPGDEDETFKDGITNGAHWYDVEGGMQDYNYVWANCFEITLELSCCKYPPASQLRQEWENNRESLITLIEKVHIGVKGFVKDSITGSGLENATISVAGINHNITTGRFGDFYRLLVPGTYNLTVVLTGYMPLTVTNVVVKEGPATEVDFSLRPTVTSVIPDTTEAVSTASTVAIPNILSGTSSSYQPIQPKDFHHHHFPDMEIFLRRFANEYPNITRLYSLGKSVESRELYVMEISDNPGVHEPGEPEFKYIGNMHGNEVVGRELLLNLIEYLCKNFGTDPEVTDLVHNTRIHLMPSMNPDGYEKSQEGDSISVIGRNNSNNFDLNRNFPDQFVQITDPTQPETIAVMSWMKSYPFVLSANLHGGSLVVNYPFDDDEQGLATYSKSPDDAVFQQIALSYSKENSQMFQGRPCKNMYPNEYFPHGITNGASWYNVPGGMQDWNYLQTNCFEVTIELGCVKYPLEKELPNFWEQNRRSLIQFMKQVHQGVRGFVLDATDGRGILNATISVAEINHPVTTYKTGDYWRLLVPGTYKITASARGYNPVTKNVTVKSEGAIQVNFTLVRSSTDSNNESKKGKGASSSTNDASDPTTKEFETLIKDLSAENGLESLMLRSSSNLALALYRYHSYKDLSEFLRGLVMNYPHITNLTNLGQSTEYRHIWSLEISNKPNVSEPEEPKIRFVAGIHGNAPVGTELLLALAEFLCLNYKKNPAVTQLVDRTRIVIVPSLNPDGRERAQEKDCTSKIGQTNARGKDLDTDFTNNASQPETKAIIENLIQKQDFSLSVALDGGSMLVTYPYDKPVQTVENKETLKHLASLYANNHPSMHMGQPSCPNKSDENIPGGVMRGAEWHSHLGSMKDYSVTYGHCPEITVYTSCCYFPSAARLPSLWADNKRSLLSMLVEVHKGVHGFVKDKTGKPISKAVIVLNEGIKVQTKEGGYFHVLLAPGVHNIIAIADGYQQQHSQVFVHHDAASSVVIVFDTDNRIFGLPRELVVTVSGATMSALILTACIIWCICSIKSNRHKDGFHRLRQHHDEYEDEIRMMSTGSKKSLLSHEFQDETDTEEETLYSSKH

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-MP0330-Ab Anti-CBPD/ CPD/ GP180 monoclonal antibody
    Target Antigen GM-Tg-g-MP0330-Ag CPD VLP (virus-like particle)
    ORF Viral Vector pGMPC001594 Human CPD Mammalian (Non-Viral Vector) plasmid


    Target information

    Target ID GM-MP0330
    Target Name CPD
    Gene ID 1362, 12874, 712407, 25306, 101081771, 480636, 532189, 100072234
    Gene Symbol and Synonyms CPD,D830034L15Rik,GP180
    Uniprot Accession O75976
    Uniprot Entry Name CBPD_HUMAN
    Protein Sub-location Transmembrane Protein
    Category Not Available
    Disease Not Available
    Gene Ensembl ENSG00000108582
    Target Classification Not Available

    The metallocarboxypeptidase family of enzymes is divided into 2 subfamilies based on sequence similarities. The pancreatic carboxypeptidase-like and the regulatory B-type carboxypeptidase subfamilies. Carboxypeptidase D has been identified as a regulatory B-type carboxypeptidase. CPD is a homolog of duck gp180, a hepatitis B virus-binding protein. Transcript variants utilizing alternative polyadenylation signals exist for this gene. [provided by RefSeq, Jul 2008]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.